Table 1_Associations between systemic inflammatory indices and the risk of renal function decline in patients with type 2 diabetes mellitus: a retrospective cohort study.docx حسب Zhi Shang (4849129)

"…</p>Conclusion<p>A significantly positive association was shown between systemic inflammatory indices and the risk of renal function decline in T2DM patients. …"

The CCDC66 depletion disrupts normal tissue organization and signaling in 3D and 2D cultures. حسب Jovana Deretic (13113617)

Table 1_Association between excessive screen time and falls, with additional risk from insufficient sleep duration in children and adolescents, a large cross-sectional study in Chi... حسب Runquan Zhang (20393850)

"…After adjusting for relevant covariates, the associations remained significant (aOR: 1.30, 95% CI: 1.08–1.56, p = 0.006; aOR: 1.43, 95% CI: 1.10–1.87, p = 0.008).…"

Supplementary file 1_Clinical application of combined anticoagulation therapy in anti-MDA5 antibody-positive associated interstitial lung disease-a retrospective study.docx حسب Ting Zhang (102583)

"…Meanwhile, C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), and Creatine Kinase (CK) levels decreased significantly. Also, the incidence of complications and acute exacerbation was lower in the combined group (P < 0.05). …"

Table 1_Integrated multi-omics analysis reveals the mechanisms of naringin in ameliorating high-fat diet-induced metabolic dysfunction-associated steatotic liver disease.doc حسب Wenping Sun (1465360)

"…Lipidomic analysis revealed that Nar restored hepatic lipid homeostasis, significantly decreasing levels of TGs and diglycerides (DGs), with 20 differentially abundant lipid species identified as potential biomarkers. …"

Data_Sheet_1_The association between Geriatric Nutritional Risk Index and KSD disease: results from National Health and Nutrition Examination Survey 2007–2018.ZIP حسب Zhicheng Tang (7010534)

"…</p>Conclusion<p>The study underscores a significant, albeit nonlinear, association between elevated GNRI levels and decreased KSD prevalence. …"

Data_Sheet_1_The association between Geriatric Nutritional Risk Index and KSD disease: results from National Health and Nutrition Examination Survey 2007–2018.ZIP حسب Zhicheng Tang (7010534)

"…</p>Conclusion<p>The study underscores a significant, albeit nonlinear, association between elevated GNRI levels and decreased KSD prevalence. …"

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…Purpose<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) increases the risk of chronic kidney disease (CKD), compounding morbidity in patients with cirrhosis. …"

Cilia disassembly proceeds at a faster rate in CCDC66-depleted cells, which is regulated by the AurkA-HDAC6 axis and rescued by microtubule stabilization. حسب Jovana Deretic (13113617)